AstraZeneca
highlights pipeline progression in i and i inhibits binding of to receptor helping to control inflammation emerging science provided confidence in phase phase trial design next gen covid additional trials in phase phase granted us fast track designation all covid variants known to date high unmet need in patients globally aiming to make available to patients in | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
26 of 45
Related slides by other companies
Equillium
Investor Presentation
February 2024
diversified pipeline of first in class immunology assets first class | Equillium
Benson Hill
Investor Presentation
October 2023
transformation to shift to a licensing model | Benson Hill
Equillium
Investor Presentation
August 2023
diversified pipeline of first in class immunology assets first class | Equillium
Equillium
Investor Presentation
December 2023
diversified pipeline of first in class immunology assets first class | Equillium
Other recent decks by AstraZeneca
See all presentations (27 decks)
Results
February 2024
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io